Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 912 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06831955RecruitingPhase 2
Lifestyle program to boost chemo before breast cancer surgery
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
AntwerpAges 18 years+ - NCT06833502RecruitingPhase 2
Screening for breast cancer spread after chemo and surgery
This trial aims to find out if doing special scans to check for breast cancer spread to organs (not just lymph nodes) is helpful in certain patients. The study looks at people with breast cancer that had already spread to lymph nodes and did not completely go away with chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06807749Recruiting
Adjuvant treatment for premenopausal breast cancer
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
Roma, Antonella PalazzoAges Up to 60 years - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06802757RecruitingPhase 2
Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Jinan, ShandongAges 18–70 - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06787339RecruitingPhase 2
Capecitabine for low-risk triple negative breast cancer
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT06781281Recruiting
Chemo plus immunotherapy for early HR+/HER2- breast cancer
This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.
ZhengzhouAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT06781762Recruiting
Breast cancer hormone therapy and its effects on heart and brain
This study looks at how starting a common hormone therapy for breast cancer (aromatase inhibitors) affects your heart and brain health over the short term. It compares women starting this treatment to healthy women who are not on the therapy.
Toronto, OntarioAges Any age - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06776458Recruiting
Aromatase inhibitor effects on heart and brain health in breast cancer
This study looks at how aromatase inhibitors (a type of hormone therapy for breast cancer) affect your heart and brain health over time. It compares women with breast cancer who have taken these drugs to healthy women of similar age.
Toronto, OntarioAges Any age - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 912 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.